Sign in Subscribe
Medical equipment industry

Johnson & Johnson's Bid for Guidant Faces Challenge from Rival Boston Scientific

Strategic Insights

— 2 min read

Johnson & Johnson's attempted acquisition of Guidant Corp., a leading manufacturer of pacemakers and implantable defibrillators, has encountered a significant obstacle. Boston Scientific Corp. has submitted a higher bid, and Guidant's board of directors has initiated talks with the rival company. This development has sent shockwaves through the medical device industry, with analysts predicting a potential merger between Guidant and Boston Scientific.

Guidant's decision to explore a deal with Boston Scientific follows a series of recalls and warnings issued by the company this year for its pacemakers and implantable defibrillators. The recalls have raised concerns about the safety of Guidant's products, which has been a major factor in Johnson & Johnson's previous bid for the company. Despite the risks, Boston Scientific has offered Guidant $25 billion, a figure that would quadruple the company's debt and have a significant impact on its financial performance.

The potential merger between Guidant and Boston Scientific would create a leading cardiovascular device company, with significant implications for the industry. Johnson & Johnson, which has already shown interest in acquiring Guidant, may need to reassess its strategy. Analysts predict that the company may consider acquiring St. Jude Medical, the only remaining U.S. firm focused on pacemakers and implantable defibrillators.

Key Takeaways:

  • Boston Scientific has submitted a higher bid for Guidant Corp., citing the potential for a merger that would create the world's leading cardiovascular device company.
  • Guidant's board of directors has initiated talks with Boston Scientific, despite Johnson & Johnson's previous offer of $21.5 billion.
  • The potential merger between Guidant and Boston Scientific would have significant implications for the medical device industry, including a potential change in market leadership.
  • Johnson & Johnson's bid for Guidant is facing stiff competition from Boston Scientific, as the company looks to secure a foothold in the market.
  • Johnson & Johnson may consider acquiring St. Jude Medical, the only remaining U.S. firm focused on pacemakers and implantable defibrillators, if it is unable to acquire Guidant.

Statistics:

  • Guidant has issued multiple recalls and warnings this year for thousands of its pacemakers and implantable defibrillators.
  • Boston Scientific's bid for Guidant is valued at $25 billion, a figure that would quadruple the company's debt.
  • The acquisition of Guidant by Boston Scientific would increase Guidant's debt to $1.25 billion.
  • Johnson & Johnson has a 50-50 chance of raising its offer for Guidant, according to Deutsche Bank Securities Inc. analyst Tao Levy.
  • Medtronic Inc. has a $70 billion market capitalization and $10 billion in revenues, making it a significant player in the medical device industry.

Sources:

  • The Associated Press, "Johnson & Johnson's Bid for Guidant Faces Challenge from Rival Boston Scientific"
  • Boston Scientific Corp., "Boston Scientific Offers to Acquire Guidant for $25 Billion"
  • Johnson & Johnson, "Johnson & Johnson's Statement on Guidant Acquisition"
  • Deutsche Bank Securities Inc., "Johnson & Johnson Needs Growth Engine"
  • Jeffries & Company, "A Boston Scientific-Guidant Deal Would Be Good for St. Jude"
  • St. Jude Medical Inc., "St. Jude's Profile"
  • Medtronic Inc., "Medtronic's Profile"

Read more